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ABSTRACT
Objective. We investigated whether 
serum soluble programmed cell death 
protein 1 (sPD-1) could predict the 
current activity and severity of antineu-
trophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) based on 
Birmingham vasculitis activity score 
(BVAS) in patients with AAV.
Methods. Fifty-nine patients from a 
monocentric prospective cohort of AAV 
were included. On the same visit-day, 
blood samples were collected and iso-
lated sera were stored, BVAS and other 
AAV-related parameters were assessed, 
and laboratory tests were performed. 
We defined the lower limit of the highest 
tertile of BVAS as the cut-off for severe 
AAV (BVAS ≥12). Serum sPD-1 was 
measured from stored serum samples. 
Results. The mean age was 59.7 years 
(38 women). The mean BVAS was 8.9 
and 18 patients had severe BVAS. Pa-
tients with severe AAV exhibited the 
higher mean serum sPD-1 than those 
without (380.7 pg/mL vs. 180.3 pg/
mL). Serum sPD-1 (r=0.367), white 
blood cell count (r=0.288), haemoglo-
bin (r=-0.590), serum albumin (r=-
0.670) erythrocyte sedimentation rate 
(ESR) (r=0.339) and C-reactive pro-
tein (CRP) (r=0.450) were significantly 
correlated with BVAS. Moreover, serum 
sPD-1 was meaningfully correlated 
with haemoglobin and serum albumin, 
but not ESR or CRP. In the multivari-
able linear regression analysis, only 
serum sPD-1 was significantly associ-
ated with BVAS (standardised β 0.274, 
p=0.024). We calculated the optimal 
cut-off of serum sPD-1 for severe AAV 
as 70.1 pg/mL. Severe AAV were more 
frequently identified in patients with 
serum sPD-1 ≥70.1 pg/mL than those 
without (RR 13.867). 
Conclusion. Serum sPD-1 could pre-
dict the current activity and severity of 
AAV.
Introduction
Programmed cell death protein 1 (PD-
1), which is one of the immune check-
point proteins, regulates immune re-
sponses related to the stimulation and 
activation of T cells by binding to 
programmed cell death-ligand (PD-
L) 1 (PD-L1) and PD-L2 producing 
inhibitory signals (1). In addition to 
a full-length isoform of PD-1, which 
has similar sequence to membranous 
PD-1, PD-1 has four different spliced 
mRNA transcripts, such as PD-1∆ex2 
(exon 2 deficiency), PD-1∆ex3 (exon 
3 deficiency), PD-1∆ex2,3 (exon 2 and 
3 deficiency), and PD-1∆ex2,3,4 (exon 
2, 3, and 4 deficiency). Among them, 
PD-1∆ex3 is responsible for producing 
soluble PD-1(sPD-1) because it pos-
sesses the extracellular domain without 
the transmembrane domain (2). Se-
creted sPD-1 binds to PD-L1 or PD-L2 
instead of PD-1 of T cells and could 
block the inhibitory effect of PD-1 on 
the stimulation and activation of T cells 
(3). PD-1 has been considered to play a 
critical role in viral hepatitis and auto-
immunity: PD-1 expression in T cells is 
increased in patients with chronic viral 
hepatitis (A); PD-1 could alleviate au-
toimmunity by calming T cell activity, 
whereas PD-1 deficiency might result 
in accelerated autoimmunity (4, 5). A 
previous study demonstrated the corre-
lation of serum sPD-1 and rheumatoid 
factor titre and 28-joint disease activ-
ity score in patients with rheumatoid 
arthritis. Furthermore, they suggested 
that pro-inflammatory cytokines, such 
as tumour necrosis factor (TNF)-α, in-
terferon (IFN)-γ and interleukin (IL)-
17, might enhance the expression of 
sPD-1 in CD4+ T cells (6).
Antineutrophil cytoplasmic antibody 
(ANCA)-associated vasculitis (AAV) is 
characterised by necrotising vasculitis 
in small-sized vessels. AAV is catego-
rised into 3 variants such as microscop-
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ic polyangiitis (MPA), granulomatosis 
with polyangiitis (GPA) and eosino-
philic granulomatosis with polyangiitis 
(EGPA) based on the 2012 Chapel Hill 
Consensus Conferences (CHCC) No-
menclature of Vasculitis (7). AAV can 
involve almost all the major organs, 
such as brain heart, lungs and kidneys, 
and furthermore, it was recently report-
ed to influence on liver, particularly, 
subclinical but significant liver fibrosis 
(B). In the pathogenesis of AAV, pro-
inflammatory cytokines prime neu-
trophils and drive them to release my-
eloperoxidase (MPO) or proteinase 3 
(PR3). Secreted MPO and PR3 are sub-
sequently presented to helper T cells by 
antigen presenting cells and contribute 
to the production of anti-MPO or anti-
PR3 ANCAs by autoreactive B cells. In 
the presence of ANCA and under the 
cytokine storm, activated neutrophils 
could initiate bulky inflammation on 
vessel walls, and then macrophages and 
T cells expand the inflammatory burden 
in adjacent tissues (8). Therefore, it is 
reasonably speculated that serum sPD-
1 can predict the current activity and 
severity of AAV like 28-joint disease 
activity score of rheumatoid arthritis 
(6). However, there is no report on the 
clinical implication of serum sPD-1in 
AAV patients yet. Hence, in this study, 
we investigated whether serum sPD-1 
could predict the current activity and 
severity of AAV based on Birmingham 
vasculitis activity score (BVAS) in pa-
tients with AAV (9). 
Patients and methods
Patients
In this study, we included 59 patients 
with AAV from our prospective Sever-
ance Hospital ANCA associated Vas-
culitidEs (SHAVE) cohort. All patients 
were first classified as AAV at the De-
partment of Rheumatology, Yonsei Uni-
versity College of Medicine, Severance 
Hospital, from October 2000 to July 
2018. They all fulfilled the 2007 Euro-
pean Medicines Agency algorithms and 
the 2012 CHCC Nomenclature of Vas-
culitis (1, 10). On the same visit-day, 
blood samples were collected and iso-
lated sera were stored, clinical manifes-
tations were reviewed and routine labo-
ratory tests were performed. Particular-
ly, on the visit-day of blood sampling, 
patients with serious medical condi-
tions other than AAV were excluded in 
this study. This study was approved by 
the Institutional Review Board of Sev-
erance Hospital (4-2016-0901) and the 
patients’ written informed consent was 
obtained at the time of blood sampling. 
AAV-related parameters 
and definition of severe AAV
On the visit-day of blood sampling, 3 
categories of AAV-related parameters 
were assessed: BVAS (9) as an index 
for the activity and severity of AAV, 
vasculitis damage index (VDI) (11) 
as a damage index, and the Korean 
version of the short form-36 (12) as a 
functional index in AAV patients. Be-
cause BVAS for GPA has a different 
weight-system compared to BVAS, we 
evenly applied BVAS to MPA, GPA 
and EGPA patients to unify the scor-
ing system. We evaluated items of both 
BVAS and VDI as clinical manifesta-
tions. We stratified AAV patients into 
three groups according to the tertile 
of BVAS and defined the lower limit 
of the highest tertile as the cut-off for 
the current severe AAV (BVAS ≥12). 
We also reviewed immunosuppressive 
drugs which were administered on the 
same day of blood sampling. 
ANCA measurement
Perinuclear (P)-ANCA and cytoplas-
mic (C)-ANCA were detected by im-
munofluorescent assay. MPO-ANCA 
and PR3-ANCA were measured by 
ELISA kit for anti-PR3 and anti-MPO 
(Inova Diagnostics, San Diego, USA) 
before 2013, and by the novel anchor 
coated highly sensitive (hs) Phadia 
ELiA (Thermo Fisher Scientific/Phad-
ia, Freiburg, Germany) using human 
native antigens, performed on a Phad-
ia250 analyser after 2013.
Laboratory data
We performed laboratory tests for vari-
ables which were previously known 
to be correlated with the activity of 
AAV. They include white blood cell 
and platelet counts (/mm3), haemoglo-
bin (g/dL), creatinine (mg/dL), serum 
albumin (g/dL), aspartate aminotrans-
ferase (AST) (IU/L), alanine ami-
notransferase (ALT) (IU/L), erythro-
cyte sedimentation rate (ESR) (mm/hr) 
and C-reactive protein (CRP) (mg/L). 
Serum sPD-1 measurement
We obtained whole blood from each 
patient with AAV, isolated serum and 
stored it at -80°c on the same day of 
collecting clinical and laboratory data. 
Serum sPD-1 was measured from 
stored serum samples using human 
PD-1 DuoSet ELISA kits (R&D sys-
tems, Minneapolis, USA) according to 
the manufacturer’s instruction.
Statistical analyses
All statistical analyses were conducted 
using SPSS software (v. 23 for win-
dows; IBM Corp., Armonk, NY, USA). 
The correlation coefficient among lab-
oratory variables was obtained using 
the Pearson correlation analysis. The 
standardised correlation coefficient be-
tween laboratory variables and BVAS 
was assessed by the multivariable linear 
regression analysis using variables with 
significant differences in the univariable 
analysis. The optimal cut-off of serum 
sPD-1 for severe AAV was extrapolat-
ed by calculating the receiver operator 
characteristic (ROC) curve. The rela-
tive risk (RR) of the optimal cut-off of 
serum sPD-1 for severe AAV was ana-
lysed using contingency tables and the 
chi square test. p-values less than 0.05 
were considered statistically significant.
Results
Baseline characteristics 
of patients with AAV
The baseline characteristics of 59 pa-
tients with AAV (21 men and 38 wom-
en) are shown in Table I. The mean age 
was 59.7 year and the mean disease 
duration was 22.8 months. Of 59 pa-
tients, 30 patients were classified as 
MPA, 18 patients as GPA and 11 pa-
tients as EGPA. The mean BVAS was 
8.9 and 18 patients had severe BVAS. 
The mean VDI and SF-36 physical and 
mental component summary were 3.1, 
50.4 and 57.9, respectively. Thirty-five 
patients had MPO-ANCA (or P-AN-
CA) and 7 patients had PR3-ANCA 
(or C-ANCA). The mean white blood 
cell and platelet counts were 8,327.6/
mm3 and 282,900.9/mm3. The mean 
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haemoglobin was 11.8 g/dL. The mean 
creatinine, serum albumin, AST, ALT, 
ESR and CRP were 1.8 mg/dL, 3.8 g/
dL, 21.7 IU/L, 22.0 IU/L, 39.4 mm/
hr and 12.1 mg/L, respectively. The 
mean serum sPD-1 was 217.5 pg/mL. 
Glucocorticoid (72.9%) was the most 
frequently administered drug, followed 
by azathioprine (23.7%) and cyclo-
phosphamide (15.3%).
Serum sPD-1 between patients 
with and without severe AAV 
and among 3 variants of AAV 
We divided AAV patients based on se-
vere AAV and compared the mean se-
rum sPD-1 between patients with and 
without severe AAV. Patients with se-
vere AAV exhibited the higher mean 
serum sPD-1 than those without (380.7 
pg/mL vs. 180.3 pg/mL) (Fig. 1A). We 
also compared the mean serum sPD-1 
among patients with MPA (229.4 pg/
mL), GPA (208.2 pg/mL) and EGPA 
(200.1 pg/mL), but we could find no 
significant difference (Fig. 1B). 
Comparison of serum sPD-1 based 
on ANCA positivity, concurrent 
immunosuppressive drugs and 
clinical manifestations
We divided AAV patients based on 
ANCA positivity, and compared se-
rum sPD-1 between the two groups. 
Forty-one patients were assigned to 
ANCA-positive AAV group and 18 
patients were to ANCA-negative AAV 
group. Patients with ANCA exhibited 
the higher mean serum sPD-1 than 
those without (235.6±338.8 pg/mL vs. 
176.3±381.5 pg/mL), but there was no 
statistical significance (p=0.554). On 
the other hands, we divided AAV pa-
tients into the two groups based on each 
immunosuppressive drug for AAV and 
compared serum sPD-1 levels between 
patients with and without each drug 
administered. Only patients receiving 
azathioprine had the higher serum sPD-
1 than those not (84.7 pg/mL vs. 28 pg/
mL, p=0.011) (Supplementary Table 
S1). In addition, we also divided AAV 
patients according to organ-based items 
of BVAS and compared serum sPD-1 
levels between patients with and with-
out each clinical manifestation. Howev-
er, there were no significant differences 
in serum sPD-1 levels between the two 
groups (Suppl. Table S2).
Correlation between laboratory 
variables
In terms of the correlation between 
BVAS and laboratory variables, serum 
sPD-1 (r=0.367), white blood cell count 
(r=0.288), haemoglobin (r=-0.590), se-
rum albumin (r=-0.670) ESR (r=0.339) 
and CRP (r=0.450) were significant-
ly correlated with BVAS (Table II). 
Moreover, in terms of the correlation 
between serum sPD-1 and other labora-
tory variables, haemoglobin (r=-0.353) 
and serum albumin (r=-0.278) were sig-
nificantly correlated with serum sPD-1, 
whereas, ESR and CRP were not corre-
lated with serum sPD-1 (Table II).
Multivariable linear regression 
analysis
We conducted the multivariable lin-
ear regression analysis with laboratory 
variables with statistical significance 
Table I. Baseline characteristics of patients 
with AAV (n=59).
Variables Values
Demographic data   
  Age (years)  59.7 ± 14.4
  Female gender (n, (%)) 38 (64.4)
  Disease duration (months) 22.8 ± 43.4
AAV Variants (n, (%)) 
  MPA 30 (50.9)
  GPA 18 (30.5)
  EGPA 11 (18.6)
AAV-specific indices 
  BVAS 8.9 ± 6.9
  VDI 3.1 ± 1.7
  SF-36 PCS score 50.4 ± 22.8
  SF-36 MCS score 57.9 ± 20.6
ANCA positivity (n, (%)) 
  MPO-ANCA or P-ANCA positive 35 (59.3)
  PR3-ANCA or C-ANCA positive 7 (11.9)
  MPO titre (Units/mL) 31.7 ± 44.8
  PR3 titre (Units/mL) 1.2 ± 4.5
Laboratory data   
  White blood cell count (/mm3) 8,327.6 ± 3,670.1
  Haemoglobin (g/dL) 11.8 ± 2.2
  Platelet count (× 1,000/mm3) 282.9 ± 99.2
  Creatinine (mg/dL) 1.8 ± 1.9
  Serum albumin (g/dL) 3.8 ± 0.6
  AST (IU/L) 21.7 ± 14.8
  ALT (IU/L) 22.0 ± 13.8
  ESR (mm/hr) 39.4 ± 32.6
  CRP (mg/L) 12.1 ± 27.1
Serum sPD-1 (pg/mL) 217.5 ± 350.1
Currently administered immunosuppressive 
drugs (n, (%)) 
  Prednisolone 43 (72.9)
  Cyclophosphamide 9 (15.3)
  Rituximab 1 (1.7)
  Azathioprine 14 (23.7)
  Tacrolimus 3 (5.1)
  Mycophenolate mofetil 2 (3.4)
  Methotrexate 2 (3.4)
Values are expressed as mean ± standard devia-
tion or number (percentages). 
AAV: ANCA-associated vasculitis; ANCA: anti-
neutrophil cytoplasmic antibody; MPA: micro-
scopic polyangiitis; GPA: granulomatosis with 
polyangiitis; EGPA: eosinophilic granulomatosis 
with polyangiitis; BVAS: Birmingham vasculitis 
activity score; VDI: vasculitis damage index; SF-
36: the short form-36; PCS: physical component 
summary; MCS: mental component summary; 
MPO: myeloperoxidase; P: perinuclear; PR3: 
proteinase 3; C: cytoplasmic; AST: aspartate ami-
notransferase; ALT: alanine aminotransferase; 
ESR: erythrocyte sedimentation rate; CRP: 
C-reactive protein; sPD-1: soluble programmed 
cell death protein 1.
Fig. 1. Serum sPD-1 according to the severity and variants of AAV. 
A. Patients with severe AAV exhibited the higher mean serum sPD-1 than those without. 
B. There were no significant differences in serum sPD-1 among MPA, GPA and EGPA patients. 
sPD-1: soluble programmed cell death protein 1; AAV: antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis; MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: 
eosinophilic granulomatosis with polyangiitis.
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in the correlation analysis for BVAS. 
Among 6 variables with significance, 
only serum albumin, but not serum 
sPD-1, was significantly associated 
with BVAS. On the other hands, we 
also performed the multivariable line-
ar regression analysis with 4 variables 
such as serum sPD-1, white blood cell 
count, ESR and CRP, as haemoglobin 
and serum albumin were remarkably 
correlated with serum sPD-1. Among 
4 variables, only serum sPD-1 (stand-
ardised β 0.274, p=0.024) was signifi-
cantly associated with BVAS (Table 
III).
Optimal cut-off of serum sPD-1 
and relative risk for severe AAV
We calculated the optimal cut-off of 
serum sPD-1 for severe AAV as 70.1 
pg/mL based on the ROC curve (AUC 
0.794, 95% CI 0.672, 0.916, sensitivity 
0.889 and specificity 0.634) (Fig. 2A). 
When we divided AAV patients into 
the two groups according to the opti-
mal cut-off of serum sPD-1, we found 
that severe AAV were more frequently 
identified in patients with serum sPD-1 
≥70.1 pg/mL than those without (51.6% 
vs. 7.1%, RR 13.867) (Fig. 2B). 
Discussion
In this study, we first investigated wheth-
er serum sPD-1 could predict the current 
activity and severity of AAV based on 
BVAS in a monocentric prospective co-
hort of AAV patients. We demonstrated 
that serum sPD-1 was significantly asso-
ciated with associated with BVAS in the 
multivariable linear regression analysis. 
We also provided an optimal cut-off of 
serum sPD-1 for severe AAV and found 
that severe AAV were more frequently 
identified in patients with serum sPD-
1 ≥70.1 pg/mL than those with serum 
sPD-1<70.1 pg/mL.
How can serum sPD-1, which is rarely 
detectable in healthy individuals (13), 
predict the current activity and sever-
ity of AAV? PD-1 has a critical role in 
regulating T cell receptor (TCR) and 
its costimulatory signals. As a conse-
quence of TCR ligation to antigen pre-
senting cell, the expression of PD-1 on 
T cells is up-regulated and furthermore, 
it may be accelerated by TCR-mediat-
ed stimulation and activation by vari-
ous pro-inflammatory cytokines (14). 
The persistent stimulation of TCR pro-
vokes the enhanced expression of PD-1 
via phosphoinositide 3-kinase and pro-
tein kinase B (Akt), leading to T cell 
exhaustion (15). On the other hands, 
as aforementioned, since sPD-1 is one 
of the splice variants of PD-1 mRNA 
transcripts (2), the expression of sPD-
1 might be increased along with the 
enhanced expression of PD-1 to coun-
teract PD-1-mediated inhibitory effects 
on T cells (14). In patients with AAV, 
infiltrating T cells are often detected in 
the tissues of vasculitis, such as kid-
neys and lungs, which is supporting 
evidence that T cells also participate in 
the late phase of AAV along with B cell 
and macrophages (16). Thus, we as-
sume that in patients with severe AAV, 
as more number of T cells are involved 




Correlation of BVAS with laboratory variables   
  Serum sPD-1 0.367 0.004
  White blood cell count  0.288 0.027
  Haemoglobin  -0.590 <0.001
  Platelet count  0.210 0.110
  Creatinine  0.239 0.069
  Serum albumin  -0.670 <0.001
  AST  -0.040 0.762
  ALT  0.228 0.083
  ESR 0.339 0.009
  CRP 0.450 <0.001
Correlation of serum sPD-1 with laboratory variables   
  White blood cell count  0.110 0.409
  Haemoglobin  -0.353 0.006
  Platelet count  0.077 0.565
  Creatinine  0.221 0.092
  Serum albumin -0.278 0.033
  AST  0.168 0.204
  ALT  0.255 0.051
  ESR 0.167 0.207
  CRP 0.232 0.077
AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; BVAS: Birmingham 
vasculitis activity score; sPD-1: soluble programmed cell death protein 1; ESR: erythrocyte sedimenta-
tion rate; CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Table III. Multivariable linear regression analysis of laboratory variables for BVAS in 
patients with AAV.
Variables Standardised β* 95% Confidence interval p-value
Among 6 variables     
  Serum sPD-1 0.149 -0.001, 0.007 0.154
White blood cell count  0.072 0.000, 0.001 0.494
  Haemoglobin  -0.204 -1.496, 0.209 0.136
  Serum albumin  -0.490 -8.772, -1.936 0.003
  ESR -0.189 -0.101, 0.021 0.194
  CRP 0.146 -0.037, 0.111 0.319
Among 4 variables*   
  Serum sPD-1 0.274 0.001, 0.010 0.024
  White blood cell count  0.135 0.000, 0.001 0.277
  ESR 0.021 -0.065, 0.074 0.898
  CRP 0.323 -0.004, 0.168 0.060
BVAS: Birmingham vasculitis activity score; AAV: ANCA-associated vasculitis; ANCA: antineutro-
phil cytoplasmic antibody; sPD-1: soluble programmed cell death protein 1; ESR: erythrocyte sedi-
mentation rate; CRP: C-reactive protein.
*Haemoglobin and serum albumin were excluded in the multivariable linear regression analysis, as 
they were remarkably correlated with serum sPD-1.
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in the pathogenesis of AAV, the stimu-
lation and activation of TCR could be 
amplified, and subsequently the tran-
scription of PD-1 could be accelerated, 
leading to an increase in serum sPD-1. 
For these reasons, we suggest that se-
rum sPD-1 could predict the current 
activity and severity of AAV.
Is serum sPD-1 correlated with circu-
lating pro-inflammatory cytokines? 
Because the expression of PD-1 and 
sPD-1 is closely related to pro-inflam-
matory cytokines activating T cells, se-
rum sPD-1 can be considered correlat-
ed with the circulating concentrations 
of these cytokines. However, it has still 
been controversial: a previous study 
reported no significant differences in 
serum IL-17 and IL-23 levels among 
patients with active AAV and healthy 
controls, whereas another previous 
study reported that different circulat-
ing cytokine levels might depend on 
ANCA specificity greater than variants 
of AAV (17, 18). We assume that there 
might be a time-sequence among the 
surge of pro-inflammatory cytokines, 
the stimulation and activation of T 
cells and the enhanced serum sPD-1: 
i) pro-inflammatory cytokines stimu-
late T cells; ii) the overstimulation of 
TCR increases the expression of PD-1 
for regulating T cell functions; iii) as 
an epiphenomenon, serum sPD-1 may 
be elevated and at the same time, circu-
lating T cell-related pro-inflammatory 
cytokines including IFN-γ and IL-17 
can be offset by the inhibitory effect 
of PD-1; iv) thus, at the time point of 
measuring serum sPD-1 in AAV pa-
tients, the range of circulating concen-
tration of pro-inflammatory cytokine 
may theoretically be wider. For these 
reasons, serum PD-1 can reflect the ac-
cumulated inflammatory burden and 
estimate BVAS independently from 
circulating pro-inflammatory cytokines 
in AAV patients.
According to the previous study, ANCA 
type was associated with serum levels 
of some cytokines, which are related 
to serum PD-1, in AAV patients (18). 
Therefore, we investigated the asso-
ciation of ANCA type and high level 
of serum sPD-1 using the chi-square 
analysis. In terms of MPO-ANCA (or 
P-ANCA), 22 of 35 AAV patients with 
MPO-ANCA (or P-ANCA) (62.5%) 
exhibited serum sPD-1 ≥70.1 pg/mL, 
whereas, 9 of 24 AAV patients without 
MPO-ANCA (or P-ANCA) (37.5%) 
exhibited serum sPD-1 ≥70.1 pg/mL. 
In other words, MPO-ANCA (or P-AN-
CA) positivity showed a tendency of 
contributing the elevated level of serum 
sPD-1, however, it was not statistically 
significant (Suppl. Fig. 1). Meanwhile, 
in terms of PR3-ANCA (or C-ANCA), 
there was no significant association be-
tween PR3-ANCA (or C-ANCA) and 
the proportion of serum sPD-1 ≥70.1 
pg/mL.
Despite the significant correlation be-
tween serum sPD-1 and BVAS, serum 
sPD-1 was not correlated with ESR 
and CRP which may meaningfully re-
flect the current activity and severity 
of AAV. Whereas, serum sPD-1 was 
negatively and remarkably correlated 
with haemoglobin and serum albumin 
which were also inversely correlated 
with BVAS. For this reason, in the mul-
tivariable linear regression analysis, we 
excluded haemoglobin and serum albu-
min among 6 variables with statistical 
significance in the correlation analysis 
and found an independent association 
of serum sPD-1 with the current activ-
ity and severity of AAV. Although we 
could not clarify this discrepancy, we 
believe a direction that is not parallel 
to traditional acute phase reactant, ESR 
and CRP, can be rather advantageous to 
predict the current activity and severity 
of AAV from diverse angles.
Serum sPD-1 was not affected ANCA 
positivity or clinical manifestations, 
but it was associated with concurrently 
administered azathioprine. patients 
receiving azathioprine had a lower 
serum sPD-1 level than those not. Al-
though the number of patients receiv-
ing azathioprine was not large enough 
to further evaluate the mechanism, we 
assumed that most patients receiving 
azathioprine might be in the status of 
inactive AAV, as azathioprine is mainly 
used as a maintenance therapeutic regi-
men. A finding that patients receiving 
cyclophosphamide and rituximab, 
which are the most widely used induc-
tion therapeutic drugs and generally 
administered to patients with severe 
AAV, exhibited higher levels of serum 
sPD-1 may support our assumption.
In this study, the mean serum sPD-1 
in all AAV patients was 217.5 pg/mL, 
but the median serum sPD-1 was only 
74.7 pg/mL. Because there was no re-
port on serum sPD-1 in AAV patients to 
date, we compared it to that in patients 
with rheumatoid arthritis and acute 
respiratory distress syndrome. A previ-
ous study reported the median serum 
sPD-1 in RA patients, similar to our 
results (around 50 pg/mL vs. 74.7 pg/
mL) (6), whereas another study report-
ed the much higher mean serum sPD-1 
in patients with ARDS than our results 
(11,429 pg/mL vs. 217.5 pg/mL) (19). 
With these results together, we assume 
that serum sPD-1 may differ in diverse 
autoimmune diseases.
Fig. 2. Optimal cut-off of serum sPD-1 and relative risk for severe AAV.
A. We calculated the optimal cut-off of serum sPD-1 for severe AAV as 70.1 pg/mL based on the re-
ceiver operator characteristic curve. 
B. Severe AAV were more frequently identified in patients with serum sPD-1 ≥70.1 pg/mL than those without. 
sPD-1: soluble programmed cell death protein 1; AAV: antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis. 
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Our study has several advantages. We 
provided valuable information on se-
rum sPD-1 in AAV and we first re-
ported the clinical implication in AAV 
patients. Since we selected patients 
based on the inclusion criteria, ob-
tained blood samples on the same day 
of assessing clinical manifestation and 
performing laboratory tests, and meas-
ured laboratory variables in their stored 
serum samples in a prospective cohort 
of AAV patients, we could overcome 
the limitations of a retrospective study 
by blocking a time-gap between clini-
cal and laboratory data. Furthermore, 
this study was conducted in a mono-
centric cohort, we could minimise the 
inter-observer variation. Also, because 
we included only Korean patients with 
AAV in our cohort, the concern on eth-
nic or geographical differences may be 
negligible.
Since the mean follow-up period of 
our prospective cohort was not longer 
than 2 years, 59 patients were included 
in this study and only 15 of 59 patients 
(25.4%) had the disease duration over 
2 years. For this reason, the number of 
patients was not large enough to repre-
sent Korean patients with AAV and fur-
thermore we could not measure serially 
serum sPD-1 with proper interval, par-
ticularly before and after induction or 
maintenance treatment, and investigate 
a dynamic change in serum sPD-1 as 
BVAS altered. Also we could not com-
pare serum sPD-1 in AAV patients with 
those in healthy individuals, as serum 
sPD-1 was not detected in controls.
However, we believe that this study is 
valuable as a pilot study to elucidate 
the clinical role of serum sPD-1 in 
AAV patients. Furthermore, future pro-
spective studies with larger AAV pa-
tients and serial measurement of serum 
sPD-1 along with BVAS will help phy-
sicians apply serum sPD-1 to the real 
clinical settings. In conclusion, serum 
sPD-1 could predict the current activity 
and severity of AAV. 
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